Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 92.6%

Neg 0% Neu 0% Pos 92.6%

Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.